Knowledge Center
Article / Oct 01, 2012
New Technologies in Particle Design. Interview: Colin Minchom, VP, Particle Design Business Unit
Source:
Drug Development and Delivery, October 2012
鈥淎n issue for customers with a poorly soluble molecule is that any one solubility enhancement technology is likely to have, I believe, a 20% to 40% probability of solving the problem. This means that in order to assure acceptable bioavailability, at least three technologies need to be investigated. The customer would need to contract with three single platform technology companies or be able to engage a single company, such as 四色AV, that can apply multiple platforms, to increase the probability of solving the聽 problem, and deliver the desired outcome.鈥
Related links
Also in the Knowledge Center
/ Apr 01, 2024
Striving for Uniformity: A Review on Advances and Challenges To Achieve Uniform Polyethylene Glycol
Read more
Scientific Article
/ May 06, 2024
Ten years of the manufacturing classification system: a review of literature applications and an extension of the framework to continuous manufacture
Read more
Scientific Article
/ Dec 28, 2023
Pharmaceutical composition containing sugar and lipid composite particles for inhalation and method for manufacturing same
Read more
Scientific Article